CRISPR THERAPEUTICS AG (NASDAQ:CRSP) Files An 8-K Results of Operations and Financial Condition
Item2.02.
|
Results of Operations and Financial Condition. |
On May11, 2017, CRISPR Therapeutics AG announced its financial
results for the first quarter ended March31, 2017.The full text
of the press release issued in connection with the announcement
is furnished as Exhibit 99.1 to this Current Report on Form
8-K.
The information in
this Form 8-K (including Exhibit 99.1) shall not be deemed filed
for purposes of Section18 of the Securities Exchange Act of 1934,
as amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
| Item9.01. | Financial Statements and Exhibits. |
(d)Exhibits:
The following
exhibits shall be deemed to be furnished, and not filed:
|
Exhibit No. |
Description |
|
| 99.1 | Press Release by CRISPR Therapeutics AG, dated May11, 2017 |
About CRISPR THERAPEUTICS AG (NASDAQ:CRSP)
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States. CRISPR THERAPEUTICS AG (NASDAQ:CRSP) Recent Trading Information
CRISPR THERAPEUTICS AG (NASDAQ:CRSP) closed its last trading session down -0.03 at 16.99 with 53,303 shares trading hands.
